KNOWLEDGE SUMMARY Question
In reported cases of iatrogenic laminitis in adult horses and ponies, is therapeutic administration of systemic corticosteroid associated with the onset of laminitis?
Clinical scenario
Horses have been reported to develop laminitis following therapeutic systemic corticosteroid administration and the risk of laminitis induced by administration of exogenous glucocorticoids remains a contentious issue in equine medicine. Previously the lack of reported adverse reactions to corticosteroids has been cited as evidence to suggest no association with laminitis. Additionally, many studies investigating the use of corticosteroids in treatment of various conditions (such as recurrent airway obstruction and musculoskeletal disorders) have not observed induction of laminitis.
It has been suspected that the development of laminitis following corticosteroid therapy is more likely in horses with an underlying disease that causes laminitis, specifically, Systemic Inflammatory Response Syndrome (SIRS) or severe systemic disease and endocrine disease. Johnson et al suggest that most widely recognised form of endocrinopathic laminitis occurs in association with steroid administration and that use of corticosteroids must be measured against the well-recognised risk of complicating laminitis (Johnson et al 2004) . Johnson et al also state the likelihood of laminitis appears to be greater with the more potent agents such as triamcinolone laminitis (Johnson et al 2004) , while an earlier review suggests the association with laminitis has not been reported for use of prednisone or prednisolone (Johnson et al 2002) .
Early in vitro research demonstrated corticosteroid potentiation of the vasoconstrictor actions of catecholamines and serotonin, suggesting the resulting venous obstruction on the hoof may cause laminitis (Eyre & Elmes 1980) . Skin perfusion was decreased in a study using six days of daily dexamethasone and the authors suggested perfusion to the hoof may also be reduced, increasing the risk of laminitis (Cornelisse et al 2006) . Following a standard overnight dexamethasone suppression test, non-obese ponies with a history of prior laminitis showed elevated insulin concentration and exaggerated production of insulin in response to corticosteroids compared to control ponies (Bailey et al 2007) . After a single administration of triamcinolone, one study reported a prolonged period (3 -4 days) of hyperglycaemia, hyperinsulinaemia and hypertriglyceridaemia (French et al 2000) . Additionally, four of the five horses in this study developed laminar rings without clinical laminitis (French et al 2000) . In a small cross-over study, healthy horses demonstrated marked insulin resistance following alternate day dexamethasone administration for three weeks (Tiley et al 2007; Tiley et al 2008) . Insulin resistance is associated with a predisposition to laminitis
Clinical bottom line
• There is currently no conclusive evidence to support a causal association between therapeutic systemic corticosteroid administration and the development of laminitis in healthy adult horses/ponies.
• There is weak evidence of an association between administration of multiple dos-es of systemic corticosteroid and the onset of laminitis in adult horses/ponies with underlying endocrine disorders or severe systemic disease.
(McGowan 2008); therefore it is possible that glucocorticoid-induced decrease in insulin sensitivity may increase the risk for development of laminitis.
Although these studies demonstrate pathophysiological effects of exogenous steroid administration which offer plausible mechanisms by which corticosteroids may induce laminitis, particularly in those animals with existing predisposing factors, they do not provide sufficient evidence to support the hypothesis of increased risk of laminitis associated with the use of steroids in clinical practice. Therefore, this knowledge summary aimed to identify cases of iatrogenic equine laminitis following systemic administration of corticosteroids and to appraise the evidence linking corticosteroid administration and laminitis onset.
The evidence
Thirteen publications, reporting a total of 40 iatrogenic cases of laminitis following systemic corticosteroid administration, were identified in the literature searches (summarised in Table 1 
Main findings: (relevant to PICO question):
• 2 of the 15 dexamethasone-treated horses developed laminitis 'a short time after discharge'. • 1 of the 2 laminitis cases was treated successfully
Limitations:
• Primary objective of the study was investigation of lung function in response to dexamethasone treatment for chronic respiratory disease.
• No clinical details presented for iatrogenic cases and corticosteroid administration not evaluated as risk factor for development of laminitis.
• Lack of temporal information precludes assessment of association between corticosteroids and onset of laminitis.
Lose (1980)
Population: 2 year old Standardbred colt attended by a first opinion equine hospital, Pennsylvania, USA Sample size: 1
Intervention details: Single intra-articular administration both tarsi. Corticosteroid and dose not reported.
Study design: Case report
Outcome studied: Objective assessment: Description of treatment of single iatrogenic laminitis case
Main findings: (relevant to PICO question):
• Onset of laminitis affecting all four feet 8 days after corticosteroid administration. Confirmed by radiographyrotation evident in all four feet (right fore most severely affected).
• No clinical details or information regarding diagnostic testing for underlying disease(s) reported. Limitations:
• Single case report, with primary focus on treatments used for laminitis.
• Provides weak evidence of association between therapeutic administration of corticosteroids and onset of laminitis in a single horse. No details presented regarding presence or absence of underlying disease.
Humber ( • Onset of mild laminitis affecting all four feet 10 days after cessation of corticosteroid administration. Confirmed by post mortem examination -slight displacement of the third phalanx in both forelimbs.
• Affected horse had evidence of systemic disease (progressive epistaxis, ecchymotic haemorrhages involving the oral mucous membranes, hyphema, petechial haemorrhages on the sclerae, and nasal and vaginal mucous membranes). The horse also had swellings in the mid cervical region over the jugular veins. Mucous membranes were pale.Mild neutrophilic leucocytosis, anaemia, hypoproteinaemic and thrombocytopenic. Blood in faeces.
Limitations:
• Single case report.
• Provides weak evidence of association between therapeutic administration of systemic corticosteroids and onset of laminitis in a single horse with severe systemic disease.
Cohen (1992)
Population: 10 year old Quarter Horse gelding referred to veterinary medical teaching hospital, Texas, USA Sample size: 1
Intervention details: 12mg (6ml) of triamcinolone administered; 2 nd treatment 3 weeks later of 10mg (5ml) of triamcinolone (injected by owner without veterinary consult); 3 rd treatment administered by owner 7 days after 2 nd second treatment (dose details unknown but suspension was much stronger (40mg/ml)).
Study design: Case report
Outcome studied: Objective assessment: Description of clinical presentation and treatment of steroid hepatopathy Main findings: (relevant to PICO question):
• Onset of bilateral forelimb laminitis 6 weeks and 6 days after first corticosteroid administration (2 weeks and 6 days after last). Confirmed by radiography -rotation evident in both fore feet.
• Affected horse had evidence of severe concurrent disease (hepatopathy and hyperadrenocorticism).
Limitations:
• Laminitis developed approximately 3 weeks following cessation of corticosteroid treatment, which does not convincingly support a causal association.
Slater (1995)
Population: Laminitis cases attended by 7 private practices and referred to veterinary medical teaching hospital, Texas, USA 
Main findings: (relevant to PICO question):
3 of 108 laminitis cases had a history of corticosteroid administration prior to the onset of clinical signs.
Limitations:
Cripps (1999)
Population: Laminitis cases referred to a specialist equine laminitis referral centre, England, UK 
Limitations:
• Primary objective of the study was investigation of clinical parameters associated with outcome of treatment for laminitis.
Frederick (2000)
Population: 23 year old American Saddlebred gelding, USA Sample size: 1
Intervention details: Single bolus injection of Naquasone (trichlormethiazide 10 mg and dexamethasone acetate 0.55 mg/ml) followed by 4 days oral administration of Naquasone tablets. Dose not reported.
Study design: Case report
Outcome studied: Subjective assessment: Owner and veterinary surgeon account of single iatrogenic laminitis case
Main findings: (relevant to PICO question):
• Onset of laminitis affecting all four feet on 4 th day of corticosteroid administration. Confirmed by radiographyrotation evident in both fore feet.
• Gelding was obese with regional adiposity (cresty neck).
• Diagnostic tests for hypothyroidism and PPID inconclusive (neither specific tests nor results reported).
Limitations:
• Very low quality non-peer reviewed single case report in journalistic style.
• Provides very weak evidence of association between therapeutic administration of systemic corticosteroids and onset of laminitis in a single aged horse with clinical signs of underlying endocrine disease • Onset of bilateral forelimb laminitis 33 days after first corticosteroid administration (23 days after last).
• Confirmed by radiography -severe rotation evident with eventual sole penetration.
• Initially referred 25 days after first corticosteroid administration for haematuria and steroid hepatopathy with weight loss, vaginal hyperaemia, leukopenia and polyuria.
• Affected horse had evidence of systemic disease (pyrexia, tachycardia, tachypnoea), congested mucous membranes, thrombophlebitis and neutrophilia).
• Laminitis developed 23 days following cessation of corticosteroid treatment, which does not convincingly support a causal association.
McCluskey (2004)
Population: Adult horses treated with triamcinolone in an equine ambulatory practice, Victoria, Australia
Sample size:
• 132 horses treated with triamcinolone (total 205 triamcinolone treatments).
• Study population included 1 iatrogenic laminitis case (7 year old Thoroughbred gelding)
Intervention details: Intra-articular administration of triamcinolone acetonide 10 mg into 4 joints (40 mg total dose)
Study design: Case series -retrospective review of clinical records
Outcome studied: Objective assessment: Prevalence of laminitis in adult horses treated with triamcinolone
Main findings: (relevant to PICO question):
• Single horse (n=1/132) developed laminitis one week after corticosteroid treatment.
• Iatrogenic laminitis case reported to have previous episode of laminitis 7 months prior. No clinical details or information regarding diagnostic testing for underlying disease(s) reported.
Limitations:
• Single case described within a case series with very limited clinical data reported.
• Provides weak evidence of association between therapeutic administration of systemic corticosteroids and onset of laminitis in a single horse with previous history of laminitis. 
Veterinary Evidence

Main findings: (relevant to PICO question):
• 4 iatrogenic acute laminitis cases reported following dexamethasone treatment.
• 3 cases euthanased due to laminitis. 4 th case treated successfully.
• Serum albumin measured in 2 of the 3 non-surviving casesboth had hypoalbuminaemia.
• Time frame of onset of laminitis relative to dexamethasone not reported.
Limitations:
• 4 laminitis cases described with very limited clinical data reported.
. Anon (2005)
Population: 14 year old mare, England, UK Sample size: 1
Intervention details:
• Dosage and nature of corticosteroids administered contested ad unclear.
• Possible intra-articular administration of triamcinolone acetonide both tarsi (1 x 80mg/2ml in each joint) OR intraarticular administration of dexamethasone both tarsi (1 x 4mg in each joint) • Multiple intra-muscular injections into back cumulatively of 20mg of dexamethasone total pages: 17
Study design: Court case transcript
Outcome studied: Subjective assessment: Transcript of summary of evidence given during court case
Main findings: (relevant to PICO question):
• Laminitis diagnosed 11 days after corticosteroid treatment.
• Euthanased due to laminitis 61 days post-diagnosis.
• Received intra-articular administration of triamcinolone right fore fetlock 4 years previously -dose not reported -no adverse events. Received multiple intra-articular and intramuscular injections of dexamethasone 2 years -dose not reported -no adverse events.
Limitations:
• No clinical details or diagnostic information reported.
• Court case assumes causal association between administration of corticosteroids and onset of laminitis. • Onset of laminitis affecting all four feet within 4 months following initiation of corticosteroid administration (possibly after 6 weeks of treatment based on Figure S5 legend in supplementary information). Initial foot soreness developed as prednisolone dose was increased to 0.8 mg/kg/day. Confirmed by post mortem examination -rotation and hoof wall separation in all four feet.
• In addition to pemphigus vulgaris, affected pony had evidence of chronic inflammation and systemic illness, considered by the authors to be contributing factors in the development of laminitis.
• Primary objective of the report was to describe the clinical, histological and immunological findings of a case of pemphigus vulgaris.
• Lack of accurate temporal information precludes assessment of association between corticosteroids and onset of laminitis. 
Veterinary Evidence
Appraisal, application and reflection
The aim of this knowledge summary was to critically appraise published evidence of iatrogenic equine laminitis following systemic administration of corticosteroids. It was beyond the scope of this review to evaluate the extensive published literature reporting on the therapeutic use of systemic corticosteroids where laminitis has not been observed or reported as an adverse event following treatment.
The 13 included publications were predominantly descriptive studies and provided low level evidence pertaining to the potential association between therapeutic administration of systemic corticosteroid and the onset of laminitis (OCEBM Levels of Evidence Working Group). No studies of an appropriate design to determine the incidence of laminitis following corticosteroid treatment or evaluate temporal relationships between corticosteroid administration and the onset of laminitis (i.e. longitudinal analytical studies) were identified.
The only observational study investigating iatrogenic laminitis following treatment with triamcinolone reported a prevalence of 0.8% (n=1/132; 95% confidence interval 0 -2.2%) (McCluskey & Kavenagh 2004 ). In the same study, three other cases of laminitis were reported, of which two were diagnosed with laminitis prior to triamcinolone but did not develop laminitis subsequent to its use. Therefore, laminitis following triamcinolone administration was observed in 33% of horses with a previous history of laminitis (n=1/3). The third horse developed laminitis 18 months after triamcinolone therapy as a result of post foaling toxaemic metritis (McCluskey & Kavenagh 2004) . Of 106 equine laminitis cases reported as adverse drug events over a 26 year period, 18% (n=19) were attributed to corticosteroid treatment, whereas 35% of cases (n=37) were attributed to administration of anthelmintics and 32% (n=34) were reported following treatment with antibiotics or antiprotozoals (U.S. FDA). (Cohen & Carter 1992) , occurred three weeks after the last dose of corticosteroid. The longer the period of time between drug administration and disease onset, the less likely the drug was a contributing factor in the aetiology due to its reduced efficacy in the body as time passes (Harkins et al 1993) . The time frame for both these two cases appears to be too long to suggest a direct causal association, especially as in both cases laminitis occurred over a week after the onset of clinical signs of systemic disease. In the remaining case, laminitis was reported to have occurred within 4 months of commencing corticosteroid treatment (Winfield et al 2013 In conclusion, no studies that sought to investigate a potential causal association between therapeutic corticosteroid administration and laminitis were identified and there is currently insufficient evidence to support such an association in healthy adult horses. There is weak evidence of an association between administration of multiple doses of systemic corticosteroid and the onset of laminitis in adult horses with underlying endocrine disorders or severe systemic disease. Therefore, underlying diseases predisposing to laminitis should be considered prior to administration of corticosteroids, particularly where multiple or large doses are indicated. However, this knowledge summary has highlighted a paucity of information on iatrogenic laminitis and a well-designed cohort study is required to quantify the apparently small risk of iatrogenic laminitis following therapeutic administration of systemic corticosteroid.
Methodology Section Search Strategy
Databases searched and dates covered:
• 
